Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
ALK-Abelló A/S
ALK makes allergy immunotherapy products—tablets, drops, and shots—plus diagnostics and adrenaline pens, for people with allergies worldwide.
ALK is an allergy company. It makes the thing that millions of people with serious allergies actually want: a way to stop being allergic. Instead of just calming symptoms with antihistamines, ALK sells immunotherapy treatments that slowly teach a person's immune system to tolerate the thing that bothers it—grass pollen, dust mites, cats, ragweed. These come as tablets you dissolve under your tongue, drops, or injections given in a clinic. The company also sells allergy diagnostics and adrenaline auto-injectors for people at risk of severe reactions.
The business rests on a simple idea from first principles. A person with a bad grass pollen allergy takes a tiny, controlled dose of grass allergen every day for months, then years. The body gradually stops overreacting. It is not a quick fix—it takes years and only works if people stick with it—but it can mean the difference between suffering every spring and barely noticing it. ALK's tablets are the big commercial bet: easy to take at home, no needles, no weekly clinic visits. That is why patients and doctors choose them over shots, and why ALK has spent heavily to get them approved and reimbursed in country after country. ALK sells mostly in Europe and North America, through prescriptions, so its revenue depends on doctors and health systems deciding the treatment is worth paying for. That is the catch. Immunotherapy is a long, slow sell, and reimbursement rules vary wildly by country. The company's tablets are its growth engine, while its older injection business and its diagnostics unit are steadier but less exciting. Adrenaline pens are a smaller but important piece—a safety net for people whose allergies can turn dangerous.
The business is not without bruises. ALK has had its share of setbacks, including a costly stumble in the US market years ago and the constant pressure of competing with other allergy players and cheaper symptom relief. Still, it is one of the few companies in the world with a broad portfolio of approved allergy immunotherapy tablets, which gives it a real moat. Its profits get plowed back into developing new tablets—for more allergens, for children—and into the slow, patient work of convincing insurers and governments to cover them. It is a quiet, unglamorous business with a genuinely useful product: helping allergic people breathe easier, season after season.
Saved answer · last researched 12 Nov 2026